Psychopharmacology

, Volume 171, Issue 1, pp 86–91

Ethical considerations in psychopharmacological research involving children and adolescents

Review

Abstract

Rationale

Increased community utilization of psychotropic medications among children has brought attention to pediatric psychopharmacology research and associated ethical issues.

Objectives

To discuss ethical aspects of child participation in psychopharmacology protocols.

Methods

Selective review of relevant scientific and regulatory literature.

Results

Efficacy and safety of psychotropics in children cannot be entirely inferred from adult data and direct participation of children in research is necessary. Child research must follow special regulations that are in addition to those common to all human research. For research with prospect of direct benefit, a critical factor is whether the risk/benefit ratio is favorable to the participating child. For research without such a prospect, the concepts of minimal risk and minor increase over minimal risk apply. However, the interpretation and application of these principles to specific protocols vary across settings and among ethics committees. Thus far, little empirical investigation has been conducted on children and parents' motivation for research participation, effectiveness of the informed consent and assent procedures, possibility of persistent consequences of exposure to experimental treatments and placebo, and validation of the concepts of minimal risk and minor increase over minimal risk.

Conclusions

Research on human subject issues relevant to child participation is a promising approach to improving ethical methods and procedures of pediatric psychopharmacology.

Keywords

Ethics Psychopharmacology Children Research 

References

  1. Agency of Health Care Policy and Research (1999) Treatment of attention deficit/hyperactivity disorder. AHCPR Publication No. 99-E017, December 1999. Rockville, Maryland, http://www.ahrq.gov/clinic/epcsums/adhdsum.htmGoogle Scholar
  2. American Academy of Pediatrics Committee on Drugs (1995) Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 95:286–294PubMedGoogle Scholar
  3. Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, Borenstein M, Bowden CL, Caplan A, Emslie GJ, Evans DL, Geller B, Grabowski LE, Herson J, Kalin NH, Keck PE Jr, Kirsch I, Krishnan KR, Kupfer DJ, Makuch RW, Miller FG, Pardes H, Post R, Reynolds MM, Roberts L, Rosenbaum JF, Rosenstein DL, Rubinow DR, Rush AJ, Ryan ND, Sachs GS, Schatzberg AF, Solomon S (2002) National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 59:262–270CrossRefPubMedGoogle Scholar
  4. Clarke GN, Rohde P, Lewinsohn PM, Hops H, Seeley JR (1999) Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry 38:272–279PubMedGoogle Scholar
  5. Coyle JT (2000) Psychotropic medications in very young children. JAMA 283:1059–1060CrossRefPubMedGoogle Scholar
  6. Department of Health and Human Services (1991a) Protection of human subjects. Basic HHS policy for protection of human research subjects. Code of Federal Regulations, Title 45, Public Welfare: Part 46, Subpart A: 46.101–46.124, Revised June 18, 1991, Effective August 19, 1991. Office of the Federal Register, National Archives and Records Administration, Washington, DC, October 1, 1994 (45 CFR Subtitle A), pp 116–127Google Scholar
  7. Department of Health and Human Services (1991b) Protection of human subjects. Subpart D: Additional protections for children involved as subjects in research. Code of Federal Regulations, Title 45, Public Welfare: Part 46, Subpart D: 46.401–46.409, Revised June 18, 1991, Effective August 19, 1991, Office of the Federal Register, National Archives and Records Administration, Washington, DC, October 1, 1994 (45 CFR Subtitle A), pp 132–135Google Scholar
  8. Emmanuel EJ, Wedler D, Grady C (2000) What makes clinical research ethical? JAMA 283:2701–2711PubMedGoogle Scholar
  9. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J (1997) A double-blind, randomized placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 54:1031–1037PubMedGoogle Scholar
  10. Emslie GJ, Rintelman J, Mayes T (2000) Are placebo-controlled trials detrimental to depressed children and adolescents? 47th annual meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, 24–29 October 2000Google Scholar
  11. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB (1990) Phenobarbital for febrile seizures—effects on intelligence and on seizure recurrence. N Engl J Med 322:364–369PubMedGoogle Scholar
  12. Food and Drug Administration (1998) Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients: final rule. Federal Register 63:66631–66672PubMedGoogle Scholar
  13. Food and Drug Administration (2000) International Conference on Harmonization; E11: Clinical investigation of medicinal products in the pediatric population. Federal Register 65:19777–19781Google Scholar
  14. Food and Drug Administration (2001) 21CFR Parts 5- and 56. Additional safeguards for children in clinical investigations of FDA-regulated products. Federal Register 65:20589–20600, http://www.fda.gov/OHRMS/DOCKETS/98fr/042401a.pdfGoogle Scholar
  15. Fost N (2001) Ethical issues in research and innovative therapy in children with mood disorders. Biol Psychiatry 49:1015–1022CrossRefPubMedGoogle Scholar
  16. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762–772PubMedGoogle Scholar
  17. Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch Gen Psychiatry 57:311–317CrossRefPubMedGoogle Scholar
  18. Kupfer DJ, Frank E (2002) Placebo in clinical trials for depression: complexity and necessity. JAMA 287:1853–1854CrossRefPubMedGoogle Scholar
  19. March JS, Biederman J, Wolkow R, Safferman A, Marekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD (1998) Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280:1752–1756CrossRefPubMedGoogle Scholar
  20. McCarthy AM, Richman LC, Hoffman RP, Rubenstein L (2001) Psychological screening of children for participation in nontherapeutic invasive research. Arch Pediatr Adolesc 155:1197–1203Google Scholar
  21. National Institutes of Health (2002) Research on ethical issues in human subjects. PA-02–103, NIH Guide, 1 May 2002, http://grants2.nih.gov/grants/guide/pa-files/PA-02–103.htmlGoogle Scholar
  22. Research Units on Pediatric Psychopharmacology Anxiety Study Group (2001) Fluvoxamine treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279–1285PubMedGoogle Scholar
  23. Research Units on Pediatric Psychopharmacology Autism Network (2001) Risperidone protocol II: results. Presentation at the 48th annual meeting of the American Academy of Child and Adolescent Psychiatry, Honolulu, HI, October 25, 2001Google Scholar
  24. Riddle MA, Kastelic EA, Frosch E (2001) Pediatric psychopharmacology. J Child Psychol Psychiatry 42:73–90CrossRefPubMedGoogle Scholar
  25. Roberts LW, Warner TD, Brody JL, Roberts B, Lauriello J, Lyketsos C (2002) Patient and psychiatrist rating of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiatry 159:573–584PubMedGoogle Scholar
  26. U.S. Congress (1997) Food and Drug Administration Modernization Act. Public Law 105–115Google Scholar
  27. U.S. Congress (2002) Best Pharmaceuticals for Children Act. Public Law 107–109Google Scholar
  28. Vitiello B (2001) Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics 108:983–989PubMedGoogle Scholar
  29. Walsh TB, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression—variable, substantial, and growing. JAMA 287:1840–1847CrossRefPubMedGoogle Scholar
  30. Zito JM, Safer DJ, dosReis S, Gardner JF, Soeken K, Boles M, Lynch F (2002) Rising prevalence of antidepressants among US youths. Pediatrics 109:721–727PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Child and Adolescent Treatment and Preventive Intervention Research BranchNIMHBethesdaUSA

Personalised recommendations